 The Company also provided an update on its clinical program to develop macimorelin for the diagnosis of child-onset growth hormone deficiency CGHD, an area of significant unmet need, and its plans to expand macimorelin for the diagnosis of adult growth hormone deficiency AGHD in Europe. With these positive Study P01 results, we have the necessary data to lay the foundation for our test validation, Study P02, which we expect to commence later this year. 